Skip to main content
Immune Tolerance Network
Developing, funding and conducting clinical trials in immune tolerance
Share This
Home

A clinical research trial for people recently diagnosed with type 1 diabetes

 

T1DAL is no longer accepting study participants

  • Home
  • Study Results
  • About T1DAL
  • New-Onset Type 1 Diabetes

Other Type 1 Diabetes Studies

Additional Type 1 Diabetes Research Studies Being Conducted by the ITN

EXTEND Preserving Beta-Cell Function with Tocilizumab in New-Onset Type 1 Diabetes

The EXTEND study is a clinical research study testing whether tocilizumab (Actemra ®) can protect remaining beta cells in individuals recently diagnosed with type 1 diabetes and extend the ability to naturally produce insulin.

For more information about the ITN and other clinical trials, please visit immunetolerance.org.

  • About ITN
  • More ITN Trials

Resources

  • Children & Clinical Studies
  • Patient Rights & Informed Consent
  • Understanding Clinical Trials
NIAID 

T1DAL is being conducted by the Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases (NIH funded), with support from JDRF. Alefacept (Amevive®) is a registered trademark of Astellas Pharma US, Inc.